XBIO - Xenetic Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6900
+0.1100 (+6.96%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.5800
Open1.5900
Bid1.6600 x 3200
Ask1.6900 x 800
Day's Range1.5803 - 1.8400
52 Week Range0.9300 - 39.0000
Volume1,864,244
Avg. Volume537,874
Market Cap9.726M
Beta (5Y Monthly)2.70
PE Ratio (TTM)N/A
EPS (TTM)-11.6360
Earnings DateMar 26, 2020 - Mar 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.50
  • ACCESSWIRE

    Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology

    The results from this single-dose study indicate that polysialylation of rFVIII confers a half-life extension similar to that of approved extended half-life products that use either PEG or Fc fusion technology and was not associated with any treatment-emergent adverse events. The Phase 1/2 clinical study was conducted by Baxalta US Inc, a Takeda company, to evaluate SHP656, which was being developed as a long-acting therapeutic for the treatment of hemophilia A utilizing Xenetic's PolyXen technology to conjugate polysialic acid to therapeutic blood-clotting factors.

  • ACCESSWIRE

    Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    - Company ramps up activities to execute XCART's preclinical and regulatory strategy - - Cash runway expected to fund Company through preclinical advancements towards IND filing - FRAMINGHAM, MA / ACCESSWIRE ...

  • ACCESSWIRE

    Xenetic Biosciences, Inc. to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

    FRAMINGHAM, MA / ACCESSWIRE / October 29, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell ("CAR T") platform technology engineered to target patient-specific tumor neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic, will present at the Dawson James Securities 5th Annual Small Cap Growth Conference on Tuesday, October 29, 2019 at 11:45 AM ET in Jupiter, FL. As part of his presentation, Mr. Eisenberg will provide a Company overview and discuss the Company's novel CAR T platform technology, called "XCART," a proximity-based screening platform capable of identifying CAR constructs that can target patient-specific tumor neoantigens, with a demonstrated proof of mechanism in B-cell Non-Hodgkin lymphomas.

  • Can Xenetic Biosciences (NASDAQ:XBIO) Fund Its Growth Plans?
    Simply Wall St.

    Can Xenetic Biosciences (NASDAQ:XBIO) Fund Its Growth Plans?

    We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

  • ACCESSWIRE

    Xenetic Biosciences, Inc. to Present at BIO Investor Forum

    FRAMINGHAM, MA / ACCESSWIRE / October 16, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell ("CAR T") platform technology engineered to target patient-specific tumor neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic, will present at BIO Investor Forum on Wednesday, October 23, 2019 at 2:45 PM PT in San Francisco, CA. As part of his presentation, Mr. Eisenberg will provide a Company overview and discuss the Company's novel CAR T platform technology, called "XCART," a proximity-based screening platform capable of identifying CAR constructs that can target patient-specific tumor neoantigens, with a demonstrated proof of mechanism in B-cell Non-Hodgkin lymphomas.

  • ACCESSWIRE

    Xenetic Biosciences, Inc. Provides Business Outlook

    FRAMINGHAM, MA / ACCESSWIRE / October 8, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell ("CAR T") platform technology engineered to target patient-specific tumor neoantigens, today provided a business outlook. "2019 is proving to be a transformational year for Xenetic, marked by the shift in our corporate strategy with our entry into the CAR T arena through the acquisition of XCART.

  • ACCESSWIRE

    Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform

    FRAMINGHAM, MA / ACCESSWIRE / July 22, 2019 / Xenetic Biosciences, Inc. (XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that it closed its previously announced $15.0 million underwritten public offering. In conjunction with the closing of the offering, Xenetic completed its previously announced acquisition of the novel CAR T (“Chimeric Antigen Receptor T Cell”) platform technology, called “XCART,” a proximity-based screening platform capable of identifying CAR constructs that can target patient-specific tumor neoantigens, which has demonstrated proof-of-mechanism in B-cell Non-Hodgkin lymphomas.

  • ACCESSWIRE

    Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering

    FRAMINGHAM, MA / ACCESSWIRE / July 17, 2019 / Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced the pricing of an underwritten public offering of 2,300,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to 2,300,000 shares of the Company’s common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined price to the public of $6.50 per share and warrant.

  • Benzinga

    Xenetic Biosciences Shares Surge After Biotech Prices Common Stock, Warrant Offering

    Nano-cap biotech Xenetic Biosciences Inc (NASDAQ: XBIO )'s stock was rallying Friday following an announcement concerning pricing for its previously announced offering of common stock and accompanying ...

  • ACCESSWIRE

    Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

    FRAMINGHAM, MA / ACCESSWIRE / June 24, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), today announced it will effect a one-for-twelve reverse stock split of its issued and outstanding common stock. Pursuant to the Certificate of Change filed with the Secretary of State of the State of Nevada, the reverse stock split will be effective at 12:01 a.m., Eastern Time, on June 25, 2019. Xenetic expects that upon the opening of trading on June 25, 2019, its common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the current trading symbol "XBIO" and the new CUSIP number 984015 503.

  • Introducing Xenetic Biosciences (NASDAQ:XBIO), The Stock That Collapsed 98%
    Simply Wall St.

    Introducing Xenetic Biosciences (NASDAQ:XBIO), The Stock That Collapsed 98%

    Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held...

  • Benzinga

    The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 13) BioSig Technologies Inc (NASDAQ: BSGM ) Milestone Pharmaceuticals ...

  • ACCESSWIRE

    Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update

    FRAMINGHAM, MA / ACCESSWIRE / May 13, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its financial results for the quarter ended March 31, 2019 and provided a corporate update. With the anticipated closing of our acquisition of XCART, our differentiated CAR T platform technology, on track for this quarter, I believe Xenetic will be well positioned to drive momentum in the innovation and development of new oncology therapeutics where there remains significant unmet need," commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.

  • ACCESSWIRE

    Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D.

    FRAMINGHAM, MA / ACCESSWIRE / May 2, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that it has appointed Guenther Koehne, M.D., Ph.D. to the Company's Scientific Advisory Board. Dr. Guenther Koehne is an internationally recognized cancer specialist and current Chief of Blood & Marrow Transplant and Hematologic Oncology at the Miami Cancer Institute.

  • ACCESSWIRE

    Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update

    FRAMINGHAM, MA / ACCESSWIRE / April 1, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its financial results for the year ended December 31, 2018. Xenetic also provided a corporate update and reviewed plans related to the Company's recently announced agreement to acquire a novel CAR T ("Chimeric Antigen Receptor T Cell") platform technology, called "XCART", as well as its oncology therapeutic XBIO-101 (sodium cridanimod), a small-molecule immunomodulator and interferon inducer which, in preliminary studies has been shown to increase progesterone receptor ("PrR") expression in endometrial tumor tissue.

  • ACCESSWIRE

    Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering

    FRAMINGHAM, MA / ACCESSWIRE / March 5, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on the acquisition, research and development of novel oncology therapeutics, including next-generation cellular immunotherapies for difficult to treat cancers, including B-cell Lymphomas, as well as improved biologic drugs, today announced it has entered into a securities purchase agreement with a single accredited institutional investor to purchase approximately $3.1 million of the Company’s common stock (the "Common Stock") (or pre-funded warrants to purchase Common Stock in lieu thereof) in a registered direct offering (the "Offering") and warrants to purchase shares of Common Stock in a concurrent private placement. The combined purchase price for one share of Common Stock (or pre-funded warrants to purchase Common Stock in lieu thereof) and each warrant will be $2.00.

  • ACCESSWIRE

    Xenetic Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform

    LEXINGTON, MA / ACCESSWIRE / March 4, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its agreement to acquire the novel CAR T ("Chimeric Antigen Receptor T Cell") platform technology, called "XCART," a proximity-based screening platform capable of identifying CAR constructs that can target patient-specific tumor neoantigens, with a demonstrated proof of mechanism in B-cell Non-Hodgkin lymphomas. The XCART technology, developed by The Scripps Research Institute ("Scripps") in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells.